Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.43 |
| ▸ | MEN1 | O00255 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TLR4 | O00206 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23932135 | 1.00 | KMT2A (0.43) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL24359191 | 0.88 | ALDH1A1 (0.36) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL2476888 | 0.85 | ALDH1A1 (0.35) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL31544797 | 0.84 | TLR4 (0.39) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL5227279 | 0.82 | NPC1 (0.33) | ALDH1A1MAPTKDM4ERAB9A | |
| SCHEMBL13039618 | 0.75 | NPC1 (0.41) | KMT2AMEN1RAB9ALMNA | |
| SCHEMBL9718446 | 0.75 | ALDH1A1 (0.49) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL4773759 | 0.74 | NPC1 (0.37) | RAB9ALMNA | |
| SCHEMBL1134463 | 0.73 | ALDH1A1 (0.53) | KMT2AMEN1ALDH1A1MAPTKDM4E | |
| SCHEMBL24249958 | 0.73 | TLR4 (0.49) | KMT2AMEN1ALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021216770-A1 | SUBSTITUTED TETRAHYDROQUINAZOLINE COMPOUNDS AS KRAS INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2021-10-28 | — | — | WO | disclosed |
| EP-3749665-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Inc. (US) | 2020-12-16 | — | — | EP | disclosed |
| US-10590115-B2 | Tetrahydroquinazoline derivatives useful as anticancer agents | PFIZER INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190248767-A1 | Tetrahydroquinazoline Derivatives Useful as Anticancer Agents | PFIZER INC. (US) | 2019-08-15 | — | — | US | disclosed |
| WO-2019155399-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2019-08-15 | — | — | WO | disclosed |
| WO-2019155399-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2019-08-15 | — | — | WO | disclosed |
| US-8618288-B2 | Pyrimidine compounds as serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-31 | — | — | US | disclosed |
| EP-1928461-B1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-04 | — | — | EP | disclosed |
| US-20100016281-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-21 | — | — | US | disclosed |
| US-7598255-B2 | Pyrimidine compounds as serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-06 | — | — | US | disclosed |
| EP-1928461-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-11 | — | — | EP | disclosed |
| US-20080132523-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-05 | — | — | US | disclosed |
| US-20080132523-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-05 | — | — | US | disclosed |
| US-7351720-B2 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351720-B2 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| US-7291744-B2 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291744-B2 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| WO-2007019083-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032481-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-08 | — | — | US | disclosed |
| US-20040259914-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248767-A1 | Tetrahydroquinazoline Derivatives Useful as Anticancer Agents | TOP2A, TOP1, TOP2B | KMT2A 1241/4885MEN1 697/4885ALDH1A1 2497/4885 |
| US-10590115-B2 | Tetrahydroquinazoline derivatives useful as anticancer agents | TOP2A, TOP1, TOP2B | KMT2A 1241/4885MEN1 697/4885ALDH1A1 2497/4885 |
| US-20070032481-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR5A, HTR6 | KMT2A 3416/4885MEN1 3805/4885ALDH1A1 3160/4885 |
| US-20080132523-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ACKR3, CCR7, CCR2 | KMT2A 4445/4885MEN1 4524/4885ALDH1A1 914/4885 |
| US-20040259914-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | ACKR3, CCR1, CXCR1 | KMT2A 4523/4885MEN1 4286/4885ALDH1A1 671/4885 |
| US-20100016281-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR5A, HTR6 | KMT2A 3416/4885MEN1 3805/4885ALDH1A1 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.